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ABSTRACT
Around mid-1995, the Molecular Endocrinology Laboratory of the
Regional Hospital (Malaga, Spain) began detecting an increase in
TSH levels in the serum of patients under study to control the treat-
ment of hypothyroidism with levothyroxine. Over a period of 5
months, of a total of 467 hypothyroid patients treated with Levo-
throid, 53% had TSH levels higher than 6 mU/mL. The reliability of
the biochemical results was verified by duplicating 56 randomly cho-
sen samples from all those with high TSH levels and by an external
control performed in four different laboratories. The amount of levo-
thyroxine in the tablets was analyzed by RIA, high performance liquid
chromatography, and their iodine contents. The lowest levels of levo-
thyroxine found in the 50-mg Levothroid tablets were those deter-
mined by RIA, with a mean value of 32.3 mg, resulting in a 35.3% loss
of activity. The mean value of levothyroxine found in these same
tablets by high performance liquid chromatography was 39.3 mg,
amounting to a 21.3% loss in activity. The iodine showed no signif-
icant loss in these tablets, with a mean experimental value of 48 mg.
The commercial laboratory withdrew lot J from the market, the one
in which these deficiencies were found. (J Clin Endocrinol Metab 82:
3192–3195, 1997)
THE APPEARANCE of synthetic preparations of levo-thyroxine in the 1950s together with the development
of highly sensitive and specific techniques for the measure-
ment of TSH seemed to enable easy control of thyroid func-
tion in hypothyroidism, but it was later found that a series
of factors could make maintenance of the euthyroid state
difficult (1, 2). Apart from individual differences regarding
intestinal absorption of the preparations (3), interference has
been reported with other medicines (2) or with the consump-
tion of fiber (4), and autoantibodies against thyroid hor-
mones have been detected (5). Divergence between the
amount of active ingredient specified on the container and
the true concentration in the tablets to be taken by the pa-
tients has also been reported (6), leading to added dosage
problems, resulting in modifications in circulating hormone
levels, especially TSH (7). Similar complications have occa-
sionally appeared with the manufacture of new presenta-
tions of the preparation or when there has been a reformu-
lation (3, 8), although a change in brand does not necessarily
result in problems (9).
When over 50% of patients treated with the same prepa-
ration of levothyroxine present elevated TSH levels, even in
the absence of clinical signs, it is necessary to analyze the
reasons for this change, which obviously has risks for the
patients (1–3). In this case it is the hormone assay that can
provide the alarm signal and that requires an adequate work-
ing strategy and assay system to determine the precise levels
of TSH and T4 (1).
Around the middle of 1995, the Molecular Endocrinology
Laboratory of the Regional Hospital (Malaga, Spain) began
to detect an increase in TSH levels in the serum of patients
under study to control the treatment of hypothyroidism with
levothyroxine. To safeguard the laboratory from any possible
responsibility, a retrospective analysis was performed, and
the biochemical thyroid function levels were followed in
those patients requiring periodic study to control their treat-
ment, with some results randomly duplicated with an alter-
native technique. This study lead to the confirmation of
raised TSH levels in those hypothyroid patients treated with
Levothroid.
We present the results of the biochemical evaluation of
treatment with Levothroid in 467 patients belonging to four
etiological groups [adult hypothyroidism (AH), thyroid can-
cer (TC), congenital hypothyroidism (CH), and pregnancy-
associated hypothyroidism (PH)] as well as data concerning
analysis of the content of levothyroxine and iodine in the tab-
lets corresponding to different pharmaceutical preparations.
Subjects and Methods
Over a period of 5 months, we studied 267 AH (160 women and 107
men), 84 CH (57 women and 27 men), 108 TC (88 women and 20 men),
8 PH, and a control group composed of 140 people with normal TSH
levels (84 women and 56 men). All patients received substitute treatment
with levothyroxine sodium (Levothroid, Rhone-Poulenc Rorer, Paris,
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France) and were attended in the Molecular Endocrinology Laboratory
by the same specialist (M.J.G.), who carried out a short interview before
the extraction of blood to ascertain any medications being taken and any
other data that could be of interest in the biochemical determination of
the results and for the preparation of the laboratory report to be sent to
the attending specialist. In the treatment controls, longitudinal fol-
low-up of the most significant parameters was compulsory. The se-
quence of the biochemical studies was determined by clinical protocols
(1, 2, 10, 11).
In Spain there are only two presentations for Levothroid tablets (50
and 100 mg), so that fractionated dosages are difficult, especially in
children. The treatment followed by our patients is extremely varied.
Patients with thyroid cancer generally use a dose between 150 and 200
mg, with corresponding personal variations. Hypothyroid adults gen-
erally use a dose between 50–150 mg depending on the clinical picture
(total or partial thyroid ablation, other treatments or pathologies, etc.).
Women increase their dosage slightly during pregnancy depending on
the state of health. Congenital hypothyroidism requires an age/weight-
dependent dosage; the initial dose used in our center is 10–15
mg/kgzday.
Experimental design
TSH and free T4 (fT4) were measured with an ultrasensitive method
by chemiluminescence (CL) in an automatic analyzer (ACS 180 Plus,
Ciba-Corning, Medfield, MA). The normal range established by the
laboratory is from 0.2–5.5 mU/mL for TSH and from 9.5–20 pmol/mL
for fT4. To check the validity of the technique, the TSH and fT4 deter-
minations were repeated for 65 randomly chosen samples from all those
subjects who had had high TSH levels. The second measurement of the
TSH hormone was made by immunoradiometric assay (IRMA; Incstar
Corp., Stillwater, MN), a technique used until 1995, with a normal range
between 0.2–5.3 mU/mL. The fT4 measurement was repeated by RIA, for
which the normal levels are 10–20 pmol.
Tablet assay
Levothroid tablets from Malaga and Madrid belonging to lot J were
analyzed together with other preparations and dosages from diverse
origins. In this report, however, we concentrate on the preparation that
led to problems in thousands of patients in Spain. The tablets were
weighed, dissolved individually in 1 mL concentrated ammonia (25%),
and vortexed for 1–2 min, after which 2 mL distilled water [high per-
formance liquid chromatography (HPLC) quality] were added, and the
mixture was again vortexed for 2–3 min. As assessed by the addition of
tracer amounts of [125I]T4, less than 0.5% of the radioactivity remained
in the pellet after centrifugation for 10 min at 2000 rpm at room tem-
perature. The supernatant was separated and used for determination of
the T4 content by HPLC and specific RIA or of the iodine content.
HPLC. A volume of supernatant containing 2 and 3 mg T4, as calculated
from the theoretical T4 content of the tablet, was injected into a C8
chromosphere (5-mm) column (100 3 3 mm) and eluted with 53% meth-
anol-47% 0.015 mol/L ammonium acetate, pH 6.0, at a flow of 0.6
ml/min, using Kontron 325 System equipment and a 332 detector (Kon-
tron Instruments, Milan, Italy). Absorbance was measured at 320 nm.
The same procedure was followed with T4 standards (T4 sodium salt
from Sigma Chemical Co., St. Louis, MO) ranging from 0.05–5.0 mg, and
the results from three different curves were introduced into the database.
The T4 content of the sample introduced into the HPLC column was
quantified automatically, using the area of the T4 peak. From this value,
the initial T4 content of the tablet was calculated.
RIA. One hundred-microliter aliquots of the supernatant were diluted
stepwise 10,000-fold using the RIA buffer (0.04 mol/L phosphate buffer,
pH 8, containing 0.2% BSA and 0.6 mmol thimerosal; Sigma Chemical
Co.) by diluting 100 mL twice to 10 mL. Twenty- and 40-mL duplicates
were submitted to a highly sensitive and specific T4 RIA, previously
described (12), and the T4 content was quantified against a T4 standard
curve run in the same assay.
I content. Twenty- and 50-mL aliquots of supernatant were digested with
chloric acid, and the iodine content was determined by the Sandell-
Kolthoff ceric-arsenite reaction, as describes by Benotti and Benotti (13);
the iodine content was quantified from iodate standards run in the same
assay. The T4 equivalents were calculated assuming all of the iodine to
be in the form of T4, using a multiplication factor of 1.53.
Two tablets were assayed from each parcel, each in duplicate, using
the three methods, and the entire procedure was repeated on three
different occasions. The mean values (6sd) are reported.
Statistical analysis
Statistical comparison of the mean levels in each group was made
using Student’s t test, and the studies were correlated using Pearson’s
test.
Results
The first modifications detected corresponded to adult
hypothyroidism in which gradually higher serum TSH levels
were seen. The significant increase in TSH in CH began to be
noticed during the first half of 1995. This group of patients
was the most closely followed due to the high number of
controls to which they were submitted (11). Retrospective
study showed the following percentages in the appearance
of high cases: first half: 1994, 8.77%; 1995, 26.31%; and second
half: 1994, 7.01%; 1995, 57.89%.
Given the increase in the number of patients receiving
treatment with high levels of TSH, the ultrasensitive CL
technique was reevaluated, comparing it with another im-
munoassay method (IRMA), with which the Molecular En-
docrinology Laboratory also had experience. The means of
the levels obtained by each technique for both TSH and fT4
showed no significant differences when Student’s t test was
applied for the nonpaired samples, although the TSH data
obtained by CL were superior to those obtained by IRMA
when these were paired (P , 0.01); there was a good cor-
relation between both methods (r 5 0.96). A multicenter
external control was also made with four laboratories that
confirmed the validity of the results.
The control group was formed by a homogeneous popu-
lation from a village near Malaga. The mean TSH level was
1.66 6 0.89 mU/mL (range, 0.32–4.2 mU/mL), and the mean
fT4 level was 15.58 6 1.68 pmol/mL (range, 11.3–19.0
pmol/mL).
Of the 267 AH, 167 (65.5%) had TSH levels higher than 6
mU/mL, 87 (32.5%) had TSH levels between 0.2–5.5 mU/mL,
and 13 (4.8%) had suppressed TSH, with levels below 0.2
mU/mL.
The 84 HC were distributed as follows: 42 patients (50%)
had TSH levels above 6 mU/mL, 38 (45%) had TSH levels
between 0.2–5.5 mU/mL, and 4 (5%) had suppressed TSH
levels that had been normal in the previous year.
Of the patients with TC, 36 (33%) had TSH levels above 6
mU/mL, and another 40 (37%) had TSH levels in the normal
range. These 2 groups with inadequate TSH levels comprised
70% of all TC receiving treatment (n 5 108). There were 32
(29%) TC with suppressed TSH.
Of the eight PH, seven (78.5%) had TSH levels above 6
mU/mL at the last control, and one (12.5%) had a normal TSH
level (Table 1 and Fig. 1). The amount of in vitro levothy-
roxine was measured by RIA, HPLC, and its iodine content
after dissolving the tablets in an ammonia solution (Table 2).
The lowest levels of levothyroxine found in the 50-mg Levo-
throid tablets were determined by RIA, with a mean level of
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32.3 mg, resulting in a 35.3% loss of activity. The mean levo-
thyroxine level in these same tablets determined by HPLC
was 39.3 mg, a 21.3% loss of activity. There was no significant
loss of iodine in these tablets, with a mean experimental
value of 48 mg. The correlations among the three techniques
were: iodine/HPLC, r 5 0.900; RIA/HPLC, r 5 0.870; and
RIA/iodine, r 5 0.969. The samples of 100 mg analyzed
presented even higher amounts than indicated by the com-
mercial laboratory.
Discussion
Control of the treatment of hypothyroidism has long been
controversial. Apart from the difficulty in establishing a per-
manent euthyroid state resulting from different individual
responses (1–3, 7, 14–16), divergence in the bioequivalence of
different commercial preparations and differences between
the amount of active ingredient indicated by the manufac-
turer and the actual dose contained in the tablets have been
reported (3, 6–8). The aim of substitution therapy with fT4
is to maintain normal TSH levels, measured with third gen-
eration assays, without the necessity of establishing a eu-
thyroid state with the TRH test (1, 2, 10).
The development of extremely sensitive tests for measur-
ing serum TSH has resulted in the attending physicians plac-
ing more trust in biochemical results than in clinical appre-
ciations when these are conflicting (16). This trust, however,
can be put to the test when a significant number of results of
biochemical evaluation of the treatment of hypothyroidism
present over a short period of time modifications in the levels
of TSH that had previously been well controlled.
In 1995, when gradual increases in TSH figures began to
be found in patients treated with levothyroxine (17, 18), it
was initially thought to be a problem related to the hormone
tests in the Molecular Endocrinology Laboratory. Apart from
both internal and external controls, the validity of the tech-
nique was checked by reevaluating a series of randomly
chosen samples from among those with high TSH levels
made with CL using an IRMA technique. The correlation
between the methods was significant; there were no differ-
ences between the means, although the TSH levels obtained
by CL were higher than those obtained by IRMA when they
were paired and contrasted. The nonmodification of the re-
maining routine values of the thyroid studies, the good
grouping in the control population, and the results of func-
tional studies also support the validity of the results.
The correlation existing between the two assay techniques
and the evolution of fT4 and TSH levels over time (Fig. 2)
suggest that the lineal drop in fT4 was due to a reduction in
the dose (3) and that the exponential increase in TSH may be
due to the normal negative feedback response of TSH to the
decrease in T4 (16, 19), which continues to be operative in
patients receiving exogenous T4 (20).
The reasons for the increased TSH levels in hypothyroid
patients undergoing treatment may be due to normal fluc-
tuations, which are very frequent when exogenous T4 is
being administered (1); lack of collaboration by the patient
(2); loss of activity of the preparation over time (6); a mod-
ification in intestinal absorption on changing lots (3); vari-
ations in the amount of active ingredient (7); interference of







Adult hypothyroidism 167 (62.5) 87 (32.5) 13 (4.8) 267
Thyroid cancer 36 (33) 40 (37) 32 (29) 108
Congenital
hypothyroidism
42 (50) 38 (45) 4 (5) 84
Totals 244 (53) 166 (36) 49 (11) 459
Percentages are given in parentheses.
FIG. 1. Distribution of the different etiological hypothyroid groups
under treatment according to TSH levels.
TABLE 2. Amount of levothyroxine in different tablets of
Levothroid determined by RIA, HPLC, and I





Sample Source RIA HPLC I
Levothroid Malaga 50 28 44 58
Levothroid Malaga 50 33 37 44
Levothroid Madrid 50 36 37 42
FIG. 2. Evolution of serum T4 and TSH levels in 42 congenital hy-
pothyroid patients who did not vary their levothyroxine dose over the
whole study period. The reduction in T4 levels is adjusted to a straight
line, but the increase in TSH levels is better adjusted to a hyperbola.
The deviation in the values on the ordinates is due to the different
control calendar followed by each patient.
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the preparation by ingested fiber (4); or a different bioequiva-
lence with the same amount of preparation (21).
Data from the analysis of pharmaceutical preparations
agree with the clinical findings. The greater loss of levothy-
roxine in the tablets from lot J, which has already been with-
drawn by the commercial laboratory, was found in the quan-
tification by RIA, which in a recent work showed normal
values (22). Quantification by HPLC showed less deficit,
whereas the amount of iodine varied very slightly compared
to the theoretical content. This might suggest a loss of bio-
logical activity due to deterioration of the tablets either dur-
ing or after the elaboration process. Both the company itself
and the Spanish Ministry of Health carried out studies on the
lots involved, agreeing that there were significant differences
in the speed of dissolution in vitro between the original prod-
uct from the U.S. and the recently imported product from
France (23), concluding that the hypothesis of bioinequiva-
lence between the tablets manufactured from the two types
of raw material was confirmed in vitro, and that it could
explain the clinical responses detected due to a lower bio-
equivalence of the tablets made from nonmicronized levo-
thyroxine, with an in vivo study of bioavailability being
unnecessary.
The clinical consequences of the data presented in this
study cannot be generalized. The CH require treatment ac-
cording to age and period of development (11, 24, 25), and
they should be reevaluated. The AH are reviewed annually,
so it is possible that further high levels of TSH will continue
appearing. Thirteen AH have suppressed TSH, which im-
plies a risk of atrial fibrillation in older persons (26). Those
pregnant women who were taking Levothroid require spe-
cial treatment. The increase in TSH that appears during preg-
nancy in hypothyroidism (2) should be borne in mind to
maintain the required euthyroid state during this period
when changing the preparation (10). Likewise, those patients
who have had their TSH normalized with an increase in the
dose of the old preparation run a severe risk of an overdose
if they maintain the same treatment with the new tablets.
Finally, the TC should be urgently reviewed given the risks
that high levels of TSH pose in these patients (2).
An additional problem is the extra cost involved in re-
evaluating all those hypothyroid patients treated with this
drug. The change in preparation is causing problems for both
patients and hospital, as the number of tests has increased by
100%. For example, between September and December 1996,
40% of the patients with thyroid cancer did not have sup-
pressed TSH levels, and 29.4% of the congenital hypothyroid
patients and 23.7% of the adult hypothyroid patients had
elevated TSH levels several months after the changeover. We
suppose that the final balance in problems of this type lies
somewhere in between the economic interests of the com-
pany, the competence of the physicians, and the demands of
the patients.
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